By using our bioinformatics expertise we optimise antibodies, so that researchers can design antibodies that are more effective in targeting specific antigens, have improved pharmacokinetic properties, and are less likely to cause adverse effects in patients. This approach can help to accelerate the development of new and effective immunotherapies for a range of diseases, including cancer and autoimmune disorders.
Our highly trained interdisciplinary team use state-of-the-art AI technologies to identify potential targets, pathways, and mechanisms of action of small molecules, which can help to accelerate the development of new and effective immunotherapies for a range of diseases, including cancer and autoimmune disorders.
Our highly trained interdisciplinary team use state-of-the-art AI technologies for developing novel approaches for Hit-to-lead identification and optimisation for an accelerated drug development workflow
Extremely committed team of biostatisticians, statistical programmers and AI engineers who help to deliver faster and meaningful information from your clinical studies
Our team of healthcare data engineers help in structuring and analysing big data to develop precision treatment solutions
Who we are?
Aomics GmbH is a deep-tech healthcare startup based in Europe, with its headquarters located in Frankfurt, Germany. Our focus is on utilising big biological data, deep learning, AI, and blockchain technologies to develop Immuno-Oncology and Immuno-Informatics Solutions.
Our company has created a personalised immuno-oncology tool called Onco-Cure. Using patient-derived tumour microenvironment (TME) data, the Onco-Cure analytical dashboard predicts specific immune biomarkers for each patient and enables oncologists to select and plan the best targeted therapies. Our goal with Onco-Cure is to provide the most insightful, approved, and personalised therapy options to oncologists within a 48-hour timeframe.
Compounds in Pipeline
Clinical PoC Trials
Technologies under development
Proof of Concept
Testing & Validation
Launch & Marketing
Scaling & Establishing
"AI empowered immuno-oncology solutions "
Who We Are
We are a German based company, specialized in the area of drug discovery and drug target identification. By leveraging state-of-the-art artificial intelligence, multi-omics and cheminformatic techniques, we efficiently reduce the time and cost of the drug development process to several folds.
“Make the best use of the state-of-the-art digital technologies, scientific knowledge and resources to accelerate the effective development of new diagnostic techniques and therapeutics for global health”
“To develop highly efficient and effective diagnostic and therapeutic techniques for a healthy future“
“To serve the patients who are unfortunately suffering with diseases with unmet medical needs by accelerating the development of highly efficient and effective diagnostic and therapeutic techniques“
Our key priority
“Our key priority is to ensure that everyone has access to safe, affordable, fast and efficient solutions to the healthcare problems, especially for the disease areas with huge unmet medical needs”
What We Do
Would you like to start a project with us?
Reach out on the given number or write us an email for further queries regarding project requirements